Corneal Crosslinking
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System
Epi-on PiXL for the Treatment of Progressive Keratoconus.
Photorefractive Intrastromal Crosslinking (PiXL) for the Treatment of Progressive Keratoconus
Surface Ablation With Corneal Cross Linking in Mild Keratoconus
Advanced Cross Linking for Low-grade Myopia
Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia